APGE•benzinga•
Apogee Therapeutics Announced Interim Phase 1 Results From Its First-in-human Trial Of APG990, The Company Says The Data Exceeded Trial Objectives And Demonstrated An Approximately 60-day Half-life
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga